Developing antibodies to fight COVID-19 using advanced technology
Structure-guided neutralizing antibodies developed using EpiVolve technology
This study is working on developing special antibodies that can fight the COVID-19 virus, using a new method to make sure they can keep up with any changes the virus might make, which could help improve treatments for COVID-19 and other infections.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abbratech, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project ID | NIH-11082180 on NIH RePORTER |
What this research studies
This research focuses on creating neutralizing antibodies that can effectively target the 2019 novel coronavirus. It employs a novel technology called EpiVolve, which systematically identifies and develops antibodies against specific sites on the virus. By overcoming immune tolerance and targeting virus-like epitopes, the approach aims to generate antibodies that can adapt to viral mutations. This could lead to more effective treatments for COVID-19 and potentially other infectious diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at high risk for COVID-19 or those who have had severe reactions to the virus.
Not a fit: Patients who are not at risk for COVID-19 or those who have already recovered without complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of highly effective antibodies that provide better protection against COVID-19.
How similar studies have performed: Other research has shown promise in developing antibodies using similar targeted approaches, indicating potential for success in this novel method.
Where this research is happening
Branford, UNITED STATES
- Abbratech, INC. — Branford, United States (Active)
Researchers
- Principal investigator: Li, Xiaofeng — Abbratech, INC.
- Study coordinator: Li, Xiaofeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.